METTL3 and gastric cancer: METTL3 enhances metastasis of GC by m6A modification of ZMYM1/E-cadherin signaling, and WTAP results in a poor clinical prognosis of GC through regulating tumor-related immune infiltration (Yue et al., 2019; Li H. et al., 2020).